Background: In Japan, production of smallpox vaccine LC16m8 (named LC16-KAKETSUKEN) was restarted and was determined to be maintained as a national stockpile in March 2002.
Objective: To conduct a post-marketing surveillance study of the vaccination of freeze-dried live attenuated smallpox vaccine prepared in cell culture LC16-KAKETSUKEN using attenuated vaccinia strain LC16m8. The study complied with Good Clinical Practice, focusing on a comparison between primary vaccinees and re-vaccinees.
Method: 268 personnel (261 males and 7 females) of the Japan Ground Self-Defense Force were inoculated with LC16-KAKETSUKEN and thereafter adverse events and efficacy were evaluated.
Results: Among 268 vaccinee participants, the following vaccinees showed adverse events, none serious: 53 of 196 primary vaccinees (without previous smallpox vaccination), 4 of 71 re-vaccinees (with previous smallpox vaccination) and 1 vaccinee with unknown previous vaccination history. A breakdown of adverse events observed in this study (total 268 vaccinees) showed the following minor or mild adverse events: 52 (19.4%) swelling of axillary lymph node, 4 (1.5%) fever, 2 (0.7%) fatigue, 1 (0.4%) of rash, 14 (5.2%) erythema at the inoculation site, 1 (0.4%) swelling at the inoculation site and 1 (0.4%) autoinoculation. The incidence of adverse events for primary vaccinees (53/196; 27.0%) was significantly higher than for re-vaccinees (4/71; 5.6%). However, the proportion of vaccine take was significantly higher for primary vaccinees (185/196; 94.4%) than for re-vaccinees (58/71; 81.7%). Although the proportion of vaccine take of re-vaccinees was significantly lower than for primary vaccinees due to preexisting immunity by previous vaccination, no significant difference was found in neutralizing antibody titers between primary vaccinees and re-vaccinees at 1, 4 and 7 months after LC16-KAKETSUKEN vaccination.
Conclusion: The present post-marketing surveillance study compliant with Good Clinical Practice demonstrated the efficacy and safety of the smallpox vaccine LC16-KAKETSUKEN in an adult population. LC16-KAKETSUKEN is the sole currently available licensed smallpox vaccine for both adult and pediatric populations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2015.09.067 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vaccine-induced T cell responses control Orthoflavivirus challenge infection without neutralizing antibodies in humans.
Nat Microbiol
January 2025
Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.
T cells have been identified as correlates of protection in viral infections. However, the level of vaccine-induced T cells needed and the extent to which they alone can control acute viral infection in humans remain uncertain. Here we conducted a double-blind, randomized controlled trial involving vaccination and challenge in 33 adult human volunteers, using the live-attenuated yellow fever (YF17D) and chimeric Japanese encephalitis-YF17D (JE/YF17D) vaccines.
View Article and Find Full Text PDFFactors associated with COVID-19 in-hospital death and COVID-19 vaccine effectiveness against COVID-19 hospitalization in the Philippines during pre-omicron and omicron period: A case-control study (MOTIVATE-P study).
Epidemiol Infect
December 2024
Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK.
COVID-19 vaccine effectiveness (VE) studies are limited in low- and middle-income countries. A case-control study was conducted among COVID-19 and other pneumonia patients admitted to a hospital in the Philippines during the pre-Omicron and Omicron periods. To elucidate factors associated with in-hospital death, 1782 COVID-19 patients were assessed.
View Article and Find Full Text PDFNuvaxovid NVX-CoV2373 vaccine safety profile: real-world data evidence after 100,000 doses, Australia, 2022 to 2023.
Euro Surveill
December 2024
Epi-Informatics, Centre for Health Analytics, Melbourne Children's Campus, Melbourne, Australia.
IntroductionNuvaxovid became available in Australia from February 2022, a year after the first COVID-19 vaccines. This protein-based vaccine was an alternative for people who had had an adverse event to and/or were hesitant to receive an mRNA or adenovirus-based COVID-19 vaccine. Although safety from clinical trials was reassuring, small trial populations, low administration rates and limited post-licensure intelligence meant potential rare adverse events were underinformed.
View Article and Find Full Text PDFBackground: Current HIV prophylactic vaccines evaluate HIV Env as purified proteins. CD40.HIVRI.
View Article and Find Full Text PDFCOVID-19 vaccination survey and anti-SARS-CoV-2 IgG responses in a human cohort from -endemic villages in Mayuge District, Uganda: a cross-sectional study.
Front Public Health
December 2024
Molecular Parasitology Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Article Synopsis
- The COVID-19 pandemic has had severe health and economic impacts globally, with vaccination being crucial for control, especially in regions with high rates of helminth infections, which could affect vaccine responses.
- A study in Uganda surveyed 450 individuals to assess helminth prevalence and COVID-19 vaccine responses; results showed high infection rates of schistosomiasis (36.4%) and hookworms (36.9%), with 93.14% vaccination coverage among a smaller group interviewed.
- Despite widespread vaccination, a significant portion of those vaccinated had low anti-S1 IgG antibody levels, indicating that helminth infections might reduce vaccine efficacy among individuals with moderate to heavy infections.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!